Abstract:Objective: To investigate the mutation of the KRAS/NRAS/BRAF/PIK3CA gene and its relationship with clinicopathological features in colorectal cancer (CRC). Methods: The surgical resection specimens of 91 patients with primary CRC from 2012 to 2016 in Shanghai Fifth People's Hospital affiliated with Fudan University were collected for retrospective analysis. Detecting mutations in the KRAS/NRAS/BRAF/PIK3CA genes were confirmed by an amplification-refractory mutation system (ARMS). Immunohistochemistry (IHC) was conducted to confirm the expression of KRAS, NRAS, BRAF, and PIK3CA proteins.Results: Among 91 CRC patients, the mutation rates of the KRAS, NRAS, BRAF, and PIK3CA genes were 40.7% (37/91), 4.4% (4/91), 3.3% (3/91) and 2.2% (2/91), respectively. The KRAS/PIK3CA double mutation rate was 2.2% (2/91), and the KRAS/NRAS double mutation rate was 1.1% (1/91). The mutation rate of the BRAF gene in poorly differentiated CRC patients was significantly higher than that in moderately to well-differentiated patients (P < 0.05). PIK3CA gene mutation was significantly different between primary tumour sites (P < 0.05). The mutation rate of the KRNS/NRAS/BRAF/PIK3CA genes in patients with lymph node metastasis (78.3%, 18/23) was significantly higher than that in patients without lymph node metastasis (45.6%, 31/68) (P < 0.05). No significant differences in immunohistochemical expression between KRAS-, NRAS-, BRAF-, and PIK3CA-mutant patients and nonmutated patients were confirmed (P>0.05). Conclusions: KRAS mutation is the most common mutated gene in CRC patients. PIK3CA mutation is often accompanied by KRAS mutation, and EGFR treatment resistance in KRAS wild-type patients may be caused by PIK3CA gene mutation. Simultaneous detection of KRAS/NRAS/BRAF/PIK3CA gene mutations helps to develop the most accurate treatment for CRC patients. KRAS/NRAS/BRAF/PIK3CA gene mutations were associated with several clinicopathological features in this group of CRC patients, but more cases need to be confirmed by further studies. Gene mutations in CRC patients are best detected by DNA sequencing or ARMS methods.Funding Information: This work was supported by the High-level Professional Physician Training Program of Minhang District, Shanghai City (No. 2020MZYS10).Declaration of Interests: None.Ethics Approval Statement: The study was approved by the Ethical Committee of Shanghai Fifth People's Hospital, Fudan University (No. 2021071). Patients did not need to give informed consent because anonymous data were used in the analysis, which were obtained after each patient's written consent to treatment.

Identification of K-RAS Codon 12, 13 and B-RAF V600E Mutation in Different Stages of Colorectal Cancer Tumorigenesis with High-Resolution Melting Analysis

Values of Mutations of K-ras Oncogene at Codon 12 in Detection of Pancreatic Cancer: 15-Year Experience

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients with Metastatic Colorectal Cancer.

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

Mutations of KRAS and BRAF in Chinese Patients with Colorectal Carcinoma : Analyses of 966 Cases

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers

Detecting KRAS mutations in colorectal carcinoma patients with high resolution melting curve analysis

[KRAS and BRAF Gene Mutations in Correlation with Clinicopathologic Features of Colorectal Carcinoma in Chinese].

Detection of KRAS,NRAS and BRAF Gene Mutations in Colorectal Carcinoma

K-ras gene mutation status in 454 Chinese patients with colorectal cancer

Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.

Detection of KRAS Mutations in Colorectal Cancer by High Resolu tion Melting Analysis

A Study on the Relationship Between KRAS, NRAS, BRAF and PIK3CA Gene Mutations and Clinicopathological Features in Patients with Colorectal Cancer

BRAF V600E Mutation and KRAS Codon 13 Mutations Predict Poor Survival in Chinese Colorectal Cancer Patients

Comparison of KRAS Mutation Status Between Primary Tumor and Metastasis in Chinese Colorectal Cancer Patients

Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients.

KRAS and BRAF Gene Mutations and DNA Mismatch Repair Status in Chinese Colorectal Carcinoma Patients.

Comprehensive analysis of gene mutations and mismatch repair in Chinese colorectal cancer patients

Detection of K-ras Gene Mutations in Cancer Tissues, Preoperative Carcinoembryonic Antigen in Serums of Patients with Colorectal Cancer and Their Correlation with Clinical Pathological Characteristics

Correlation Between Clinicopathological Features and KRAS, NRAS, and BRAF Mutation Status in Chinese Colorectal Cancer Patients

Retrospective analysis of KRAS, NRAS and BRAF gene mutations and clinicopathological features in patients with colorectal cancer